SAGILITY INDIA Q2 FY27 : EBITDA MARGIN GUIDANCE RAISED TO 25–26%, DOUBLE-DIGIT ORGANIC GROWTH & CHIROC ACQUISITION

• FY27 ADJUSTED EBITDA MARGIN GUIDANCE RAISED TO 25–26% FROM EARLIER 24–25% • FY27 ORGANIC REVENUE GROWTH GUIDANCE MAINTAINED AT LOW DOUBLE DIGITS IN CONSTANT CURRENCY • H2 FY27 REVENUE EXPECTED TO BENEFIT FROM SEASONAL OPEN ENROLLMENT ACTIVITIES • OPEN ENROLLMENT REVENUE CONTRIBUTION EXPECTED TO DECLINE APPROXIMATELY 100 BPS VS LAST YEAR • MEDIUM-TERM ADJUSTED EBITDA MARGIN EXPECTED TO REMAIN AROUND 24–26% • CHIROC HEALTH ACQUISITION COMPLETED FOR $20 MN UPFRONT, WITH POTENTIAL $12.35 MN EARNOUT • CHIROC REPORTED APPROXIMATELY $13 MN ANNUAL REVENUE & 35.8% ADJUSTED EBITDA MARGIN • PROVIDER BUSINESS TARGETED TO GROW FASTER & INCREASE ITS CONTRIBUTION FROM CURRENT 10.1% • CHIROC ACQUISITION EXPECTED TO ENABLE LARGER END-TO-END REVENUE CYCLE MANAGEMENT DEALS • CROSS-SELLING OPPORTUNITIES EXPECTED ACROSS EXISTING PAYER & PROVIDER CLIENTS • AI-LED AUTOMATION IN CLAIMS PROCESSING & REVENUE CYCLE MANAGEMENT EXPECTED TO SUPPORT PRODUCTIVITY • MANAGEMENT EXPECTS TO RETAIN SOME AI EFFICIENCY BENEFITS WHILE PASSING MAJORITY TO CLIENTS • NEW DEAL ANNUAL CONTRACT VALUE UP 18.2% YOY TO $40.2 MN • COMPANY TURNED NET CASH POSITIVE AT ₹112.7 CR; CONTINUED INVESTMENT IN TECHNOLOGY & SELECTIVE ACQUISITIONS PLANNED • SOFTER ENROLLMENT REVENUE, SLOWER ORGANIC PROVIDER GROWTH & AI-RELATED PRICING PRESSURE REMAIN KEY RISKS

SAGILITY LIMITED

← Back to feed